13 research outputs found
Loop corrections for Kaluza-Klein AdS amplitudes
Recently we conjectured the four-point amplitude of graviton multiplets in
at one loop by exploiting the operator product
expansion of super Yang-Mills theory. Here we give the first
extension of those results to include Kaluza-Klein modes, obtaining the
amplitude for two graviton multiplets and two states of the first KK mode. Our
method again relies on resolving the large N degeneracy among a family of long
double-trace operators, for which we obtain explicit formulas for the leading
anomalous dimensions. Having constructed the one-loop amplitude we are able to
obtain a formula for the one-loop corrections to the anomalous dimensions of
all twist five double-trace operators.Comment: 37 pages. One ancillary file containing data on the correlator
Age-adjusted baseline characteristics among 727 postmenopausal women in the California Teachers Study diagnosed with lung cancer stratified by history of menopausal hormone therapy (MHT) use.
1<p>Race/ethnicity analysis was not adjusted for by age.</p>2<p>Other category for race/ethnicity includes: African American, Hispanic, Native American, Asian/Pacific Islander, Mixed and Unknown.</p>3<p>Mean pack-years calculated only among ever smoking women.</p
Study populations and exclusions for model development: NIH-AARP and PLCO cohorts at baseline.
<p>Study populations and exclusions for model development: NIH-AARP and PLCO cohorts at baseline.</p
Examples of 10- and 20-y absolute risk estimates for breast, endometrial, and ovarian cancer using SEER rates corrected for hysterectomy for endometrial cancer and for oophorectomy for ovarian cancer in non-Hispanic, white women.
<p>C, current; F, former; N, no; NA, not applicable; Y, yes.</p
Breast cancer risk predictions during the follow-up of non-Hispanic, white women in the NHS for new breast cancer model and BCRAT.
<p>NA, not applicable.</p
Adjusted<sup>1</sup> hazard ratios (HR) and 95% confidence intervals (CI) for the association between menopausal hormone therapy (MHT) use and mortality among 727 postmenopausal women diagnosed with lung cancer following enrollment in the California Teachers Study.
1<p>Cox proportional hazards regression models using age (in days) as the time metric and stratified by age (in years) with the adjustment for race, a variable combining smoking status and pack-years (never smoker, former light smoker, former heavy smoker, current light smoker, current heavy smoker) and stage.</p><p>**All variables measured at baseline.</p
Selected characteristics of non-Hispanic, white women in the NIH-AARP and PLCO cohorts.
<p>NA, not applicable.</p
Study population and exclusions for model validation: NHS cohort at baseline.
<p>Study population and exclusions for model validation: NHS cohort at baseline.</p
Age-specific incidence per 100,000 person-years in non-Hispanic white women from the NHS cohort, excluding only women with prevalent cancer of interest and no positive follow-up time.
a<p>Cancer of the corpus uteri or uterus, not otherwise specified.</p
Kaplan-Meier curves of lung cancer-specific survival by ever and never MHT use.
<p>Ever MHT use: n = 297 deaths/511 cases; Never MHT use: 144 deaths/216 cases. MST = median survival time.</p